NCT01392547 - Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

Interventions

DRUG

vatreptacog alfa (activated)

1-3 doses per bleeding episode

DRUG

eptacog alfa (activated)

1-3 doses per bleeding episode

Trial Locations (32)

500

Changhua

2193

Parktown, Johannesburg

10400

Bangkok

11219

Novo Nordisk Clinical Trial Call Center, Brooklyn

20124

Milan

21000

Novi Sad

23219

Novo Nordisk Clinical Trial Call Center, Richmond

30322

Novo Nordisk Clinical Trial Call Center, Atlanta

30912

Novo Nordisk Clinical Trial Call Center, Augusta

33607

Novo Nordisk Clinical Trial Call Center, Tampa

35100

Bornova-IZMIR

50400

Kuala Lumpur

52242

Novo Nordisk Clinical Trial Call Center, Iowa City

80045

Novo Nordisk Clinical Trial Call Center, Aurora

90007

Novo Nordisk Clinical Trial Call Center, Los Angeles

90027

Novo Nordisk Clinical Trial Call Center, Los Angeles

92868

Novo Nordisk Clinical Trial Call Center, Orange

97239

Novo Nordisk Clinical Trial Call Center, Portland

191186

Saint Petersburg

300011

Timișoara

13081970

Campinas

85724-0001

Novo Nordisk Clinical Trial Call Center, Tucson

02115

Novo Nordisk Clinical Trial Call Center, Boston

48202-2608

Novo Nordisk Clinical Trial Call Center, Detroit

A 4020

Linz

10 000

Zagreb

GR-11527

Athens

H-1134

Budapest

160 0023

Shinjuku-ku, Tokyo

02-776

Warsaw

00935

Novo Nordisk Clinical Trial Call Center, San Juan

OX3 7LJ

Oxford